Background
==========

Over the last decades numerous epidemiological studies have clearly shown that urban air pollution can produce a variety of adverse health effects \[[@B1],[@B2]\]. Ambient particulate matter (PM) either characterized as the mass concentration of particles less than 10 μm (PM~10~) or less than 2.5 μm (PM~2.5~) are considered to be the major culprit. Therefore, current air quality standards or guidelines refer to PM~10~ and/or PM~2.5~\[[@B3],[@B4]\]. However, in reality ambient PM is a mixture of coarse (2.5-10 μm), PM~2.5~ (named also fine particles) and ultrafine (\<0.1 μm) particles generated from different processes, having variable chemical composition and atmospheric behavior. It should also be noted that although the ultrafine fraction accounts for less than 1% of the mass of particulate matter, it represents the greatest proportion in terms of number of particles (typically \>80%) \[[@B5]-[@B7]\]. Furthermore, the mechanism and the fraction of PM that are mainly responsible for the observed health effects is a matter of controversy \[[@B1]\]. In 1995 Seaton hypothesized that the number of ultrafine particles may be a more health relevant property than the usually measured mass of inhaled PM~10~ and PM~2.5~\[[@B8]\]. This is because of the greater surface area available to react with epithelial and inflammatory cells in the lung and because of the capacity of ultrafine particles to penetrate deeper in the lung parenchyma, potentially reaching the circulation and exerting adverse biological effects by releasing toxic free radicals \[[@B8]-[@B11]\]. In meantime other studies were published, however, the role of ultrafine particles is still under discussion \[[@B9],[@B12]-[@B14]\].

The only systematic review of studies that have analysed fine and coarse PM jointly demonstrates that the health effects of coarse particles are significant and should not be overlooked \[[@B15]\]. Thus, special consideration should be given to each fraction of the particles and their effects on health. Better characterization of the health relevant particle fraction will have major implications for air quality policy since it will determine which sources should be controlled.

The RUPIOH (Relationship between Ultrafine and fine Particulate matter in Indoor and Outdoor air and respiratory Health) is an EU-funded multicentre study designed to examine the distribution of various particle metrics both indoors and outdoors in four European cities and assess their health effects in individuals with asthma or chronic obstructive pulmonary disease (COPD), based on a detailed exposure assessment. The study consisted of two parts: i) the diary study in which participants were asked to complete a daily diary for six months while exposure was assessed based on a central site measurements and ii) the intensive week measurements during which, for each subject, more intensive health and exposure measurements were conducted. In this paper, we report the association of ambient PM~10~, PM~2.5~, coarse particle mass (PM~10-2.5~) and particle number concentrations (PNC), measured at the central site, with respiratory symptoms and limitation in activities due to breathing problems in participants having either asthma or COPD who have been followed for six months. Associations of the health outcomes with gaseous air pollutants were also examined based on data collected from existing national monitoring networks in each country. The relationships between central site outdoor, residential outdoor and indoor concentrations, as well as the association between outdoor and indoor exposure to fine and ultrafine particles and lung function in the same participants but based on the intensive week measurements have been published before \[[@B16]-[@B20]\].

Methods
=======

Study design
------------

In the context of RUPIOH, a multicentre study was conducted from October 2002 to March 2004 in four European metropolitan areas, namely, Amsterdam (The Netherlands), Athens (Greece), Birmingham (United Kingdom) and Helsinki (Finland). During the whole study period a central site in each city was used to monitor particle mass and PNC on a daily basis. At various locations covering the entire metropolitan area, homes of participants with either asthma or COPD were selected. The criteria for the central site and homes selection have been described in detail in a previous publication \[[@B17]\]. Respiratory health status of each participant was monitored for six months by a daily symptom diary. We used a staged entry of the participants (based on the real date the participants started to fill out the diaries) in order to increase the period of data collection and thus, decrease the likelihood for uncontrolled factors or unexpected events to influence the associations between air pollution and health \[[@B21]\]. In all centres, participants were recruited between October 2002 and March 2004.

Study population
----------------

Inclusion criteria and recruitment procedures have been described in detail before \[[@B19]\]. Briefly, in each city the recruitment criteria for participants were age 35 or more, a doctor diagnosis of either asthma (as defined by Global Initiative for Asthma) or COPD (as defined by Global Initiative for Chronic Obstructive Lung Disease) and having had experienced respiratory symptoms in the past 12 months \[[@B22],[@B23]\]. Especially, in the Netherlands some patients who had not received a definite diagnosis of asthma or COPD were classified as chronic non-specific lung disease (CNSLD) as a relic of tradition (term previously used to indicate either asthma or COPD) \[[@B24]\]. Severe patients defined as those using relief bronchodilating medications more than three times per day or using nebulised bronchodilators or long-term oxygen therapy as well as participants unable to perform a satisfactory spirometry test were excluded from the study. An attempt was made to select non-working, non-smoking patients living in a non-smoking household to eliminate potential confounding by occupational exposures to airborne particles and by environmental tobacco smoke. The same screening questionnaire was used across the four centres to ascertain eligibility. However, each centre was allowed to choose the optimal subject recruitment method. Specifically, in Amsterdam, the panelists were recruited through distribution of 10,000 information letters accompanied by screening questionnaires. Inclusion criteria were checked using the returned screening questionnaires followed by participants' homes' visits. In Athens, subjects recruited through local hospitals and pulmonary chest physicians were visited at home by a pulmonologist (A.K.) and one of the investigators of the exposure assessment team (I.K.) who checked whether inclusion criteria were met. In Finland, subjects were selected from the Helsinki Metropolitan Area (including cities of Helsinki, Espoo and Vantaa) by placing advertisement on two issues of the respiratory patient association magazine (circulation \~3500 households) and notice boards of pulmonary disease clinics of four major hospitals within the study area. Candidate subjects were interviewed and screened by telephone and invited to an information session when they met the criteria. In the United Kingdom, potential study subjects living in the greater area of Birmingham were selected from the Clinic for Respiratory illnesses (CRI) database of respiratory patients at the Heartlands Hospital. Privacy regulations restricted the selections to only those that had given their written consent to be approached for research studies.

Medical ethical clearance was acquired from the relevant local medical ethics committees in all centres before the start of the recruitment. Written informed consent was obtained from each subject.

Symptom diary
-------------

The diary was based upon diaries used in previous studies of acute effects of air pollution such as the PEACE study \[[@B21]\]. Although there is no real objective method of validating symptoms, a previous study by Hoek et al. provide evidence that symptoms, assessed with the same diary, are reflected in lung function drops \[[@B25]\]. Participants were instructed to complete a daily record about respiratory symptoms and medication taken "as needed" for six months, grading shortness of breath, wheeze, cough, phlegm and woken with breathing problems as absent (0), slight (1), or moderate/severe (2). In addition, they were asked about any limitation in performing daily life activities categorized as vigorous (such as running, lifting heavy objects, participating in strenuous sports), moderate (such as moving a table, pushing a vacuum cleaner, bowling or playing golf), walking one block/climbing one flight of stairs and leaving one's home, because of breathing problems. This limitation could be reported in three grades: no limitation (0), yes, did activity slowly (1) and yes, avoided activity completely (2). Questions on whether they have been outside the house or town and for how long have also been included.

During the study period there was personal contact with the participants once a month to collect the completed diary forms, discuss potential problems and keep the motivation at a good level.

Air pollution exposure
----------------------

Exposure assessment has been described in previous publications \[[@B16]-[@B18],[@B20]\]. In brief, during the entire study period (October 2002 to March 2004) in each city measurements of PM~2.5~, PM~10~ and PNC were performed continuously at a central site representing urban background levels \[[@B17]\]. The same type of condensation particle counter (TSI 3022A, TSI Inc., St. Paul, MN, USA) was used in each city to monitor PNC. 24-hour average particle mass concentration was measured with Harvard impactors for PM~2.5~ and PM~10~. Coarse particles concentrations were calculated by subtracting PM~2.5~ from PM~10~. After weighing, the absorbance of the PM~2.5~ filters (a good surrogate for elemental carbon/soot) was determined using reflectometry. PNC was transformed to "noon-to-noon" 24-hour means to coincide with the PM~2.5~ measurements. Data on concentrations of other air pollutants (ozone, nitrogen dioxide) and meteorology (air temperature, relative humidity) were collected from existing national monitoring networks in each country. We did not replace missing values in exposures variables by imputation.

Confounder data
---------------

Time trend in health endpoints (e.g. fatigue in reporting), weather (outdoor temperature, relative humidity), medication use and day of the week were taken into account as potential confounders. Because of the staged entry of participants, we evaluated two time variables: calendar date (proxy for unmeasured confounders) and day of study for a specific subject (possibly related to fatigue).

Quality assurance/quality control
---------------------------------

Air pollution and health measurements were performed according to standard operating procedures (SOPs). A training workshop was organized before the start of the fieldwork and site visits were implemented during the fieldwork to identify any deviations from SOPs.

Statistical analysis
--------------------

Data analysis was done according to a predefined analysis plan. The symptom variables, initially coded as 0 for no symptoms (absent), 1 for slight symptoms and 2 for moderate/severe symptoms, were dichotomised for the analysis by setting 0 for no symptoms and 1 for slight to moderate/severe symptoms. Each symptom was analysed separately either as prevalent (irrespective of its occurrence on the previous day) or incident (when that symptom was reported to be absent on the previous day). Medication use was coded as 0 (no medication) versus 1 (intake of one or more doses) independently of the initial medication group. Every person was included in the analysis regardless of how many diary entries were made. Moreover, diary entries were excluded when participants had left the study area during the measurement period. For every pollutant the following lags were evaluated: lag 0, 1, 2 and the average of lag 0--6 days. Lag 0 was defined as the 24-hour period starting from noon of the calendar day before the health response.

A hierarchical modelling approach was used. First, regression models were fitted in each city separately to allow specific control for seasonal effects, weather and other potential confounders. Results of the individual city analysis were used in a second stage analysis (meta-analysis) to provide overall estimates \[[@B26]\]. We computed both fixed and random effects combined estimates. Furthermore, a chi-square test of heterogeneity of the four city-specific estimates was computed.

We applied logistic regression to obtain centre-specific effect estimates. A smooth function (natural splines with 6 degrees of freedom per year) of time was used to remove the seasonal patterns and long time trends from the data. Afterwards, same-day (lag 0) and previous-day (lag 1) mean daily temperatures were introduced simultaneously into the model. For both lags of temperature, a linear term was compared with a smoothed function (natural splines) with 2, 3 and 4 degrees of freedom and the model with the lowest Akaike's Information Criterion (AIC) was selected. A linear term of relative humidity (lag 0) was added to the model as another indicator of weather. Finally, indicator variables for day of the week, medication use and individual differences in frequency of symptoms, were added to the model. After setting up the baseline model, the effects of the various lags of the pollutants were evaluated.

In the city specific analysis we fitted fixed effects models, described above, as well as random intercept logistic regression models using "glmmPQL" function from MASS library in R software, to take into account the correlation among each subject's measurements. Results from the random effects analysis were very similar to those derived from fixed effects. In a few cases though, we faced convergence issues. This was even more the case when we tested a first order autoregressive correlation structure. The significance of the associations was similar between random intercept models and the models incorporating an autoregressive term.

Because of the heterogeneity of the study population, we repeated the analysis (for all air pollution measures) for the subgroup of asthmatic patients. There were not enough COPD patients to analyse these patients separately. We also fitted two pollutant models by including simultaneously PM~2.5~ and PM~10-2.5~ in order to better characterize which of the two components of PM~10~ (PM~10-2.5~ or PM~2.5~) was responsible for the observed health effects.

Effect estimates are expressed as odds ratios (OR) for an increase of 10 μg/m^3^ in PM~10~, 10 μg/m^3^ in PM~2.5~, 10 μg/m^3^ in PM~10-2.5~, 10,000 particles/cm^3^ for PNC and 1·10^-5^ m^-1^ for absorbance, in order to be comparable with other studies. For gaseous pollutants the effect estimates are expressed as OR for an increase of 10 μg/m^3^ in ozone and NO~2~ concentrations.All analyses were performed using R software \[[@B27]\].

Results
=======

Panel characteristics
---------------------

A brief description of the study population is presented in Table [1](#T1){ref-type="table"}. Mean age and age range were about the same in all cities. Three participants in Athens were slightly below of the recruitment criterion of ≥35 years. In Amsterdam a large group was reported to have CNSLD. Medication use was high in the panels. Seventy seven per cent of the participants (77%) used reliever medication. Use of "as needed medication" was recorded in 26.5% of total person days in Helsinki, 13.9% in Athens, 37.9% in Amsterdam and 59.7% in Birmingham. Twenty-nine participants (21%) worked outside their home especially from Amsterdam and Birmingham. Those who worked outside their home, worked on average 19 h/week.

###### 

Characteristics of four European panels of asthmatic/COPD patients

                                 **Helsinki**   **Athens**   **Amsterdam**   **Birmingham**                              
  ------------------------------ -------------- ------------ --------------- ---------------- ------ ------------ ------ ------------
  Male /Female                   6 / 30         19 / 16      10 / 26         7 / 22                                      
   Asthma                        3 / 28         6 / 13       3 / 8           6 / 21                                      
   COPD                          3 / 1          12 / 3       2 / 7           1 / 0                                       
   Other^b^                      0 / 1          1 / 0        5 / 11          0 / 1                                       
  Age^c^                         63.5           \[36--85\]   62.2            \[33--84\]       63.3   \[46--77\]   60.1   \[37--76\]
   Asthma                        62.9           \[36--85\]   55.7            \[33--77\]       62.8   \[46--77\]   59.6   \[37--76\]
   COPD                          65.0           \[57--74\]   68.7            \[45--84\]       63.7   \[59--72\]   53.0   \-
   Other^b^                      75.0           \-           78.0            \-               63.2   \[46--77\]   69.0   \-
  Asthma                         31             (86%)        19              (54%)            11     (31%)        27     (93%)
  COPD                           4              (11%)        15              (43%)            9      (25%)        1      (3.5%)
  Asthma + COPD                  1              (3%)         1               (3%)             4      (11%)        1      (3.5%)
  CNSLD^d^                       0              (0%)         0               (0%)             12     (33%)        0      (0%)
  **Smoking status**                                                                                                     
  Never smoker                   26             (72%)        15              (43%)            13     (36%)        15     (52%)
  Current                        0              (0%)         1               (3%)             0      (0%)         3      (10%)
  Ex-smoker                      10             (28%)        19              (54%)            23     (64%)        11     (48%)
  ETS^e^ exposure at home        0              (0%)         5               (14.7%)          0      (0%)         1      (3.4%)
  **Medication use**                                                                                                     
  Short acting β2-agonist        24             (67%)        9               (26%)            16     (44%)        28     (97%)
  Reliever medication^f^         29             (81%)        21              (62%)            25     (69%)        29     (100%)
  Inhaled glucocorticosteroids   34             (94%)        28              (82%)            27     (75%)        24     (83%)
  Oral glucocorticosteroids      5              (14%)        5               (15%)            6      (17%)        6      (21%)
  **On need medication use**                                                                                             
  Short acting β2-agonist        18             (50%)        8               (24%)            14     (39%)        28     (97%)
  Reliever medication^f^         22             (61%)        21              (62%)            18     (50%)        29     (100%)
  Inhaled glucocorticosteroids   6              (17%)        18              (53%)            7      (19%)        5      (17%)
  Oral glucocorticosteroids      3              (8%)         5               (15%)            4      (11%)        5      (17%)

^a^ Total participants in panel.

^b^ Asthma + COPD or chronic non-specific lung disease.

^c^ Given as mean and \[range\].

^d^ Chronic non-specific lung disease.

^e^ Environmental tobacco smoke.

^f^ Includes short acting β2-agonist, long acting β2-agonist, anticholinergic drugs and combination of an anticholinergic drug and a β2-agonist.

Symptoms
--------

In total between 4,760 and 6,003 person days were available for analysis in the four cities. In Amsterdam, Athens and Birmingham participants filled out the diary from October 2002 to March 2004 whilst in Helsinki between October 2002 and February 2004. Missing values (person days) ranged between 9.4-15.1% in Amsterdam, 4.7-5.5% in Athens, 8.7-8.8% in Birmingham and 8.6-12.1% in Helsinki. Consistent with the composition of the panel, fairly high symptom prevalence occurred during the study period. Person days with severe symptoms were low, except for cough and phlegm. There were small differences between the cities (Table [2](#T2){ref-type="table"}).

###### 

Person days with symptoms in the diary (n = number of expected person days)

                                                 **Helsinki**   **Athens**   **Amsterdam**   **Birmingham**                        
  ---------------------------------------------- -------------- ------------ --------------- ---------------- ------ ------ ------ ------
  **Woken with breathing problems**                                                                                                
  No                                             4759           73.4         5334            84.7             4897   75.6   3953   75.7
  Yes                                            978            15.1         667             10.6             958    14.8   808    15.5
  Non response                                   743            11.5         299             4.7              625    9.6    459    8.8
  **Shortness of breath**                                                                                                          
  No                                             3987           61.5         4891            77.7             3410   52.6   3111   59.6
  Slight symptoms                                1774           27.4         1015            16.1             2179   33.6   1443   27.6
  Severe symptoms                                140            2.2          96              1.5              284    4.4    206    4.0
  Non response                                   579            8.9          298             4.7              607    9.4    460    8.8
  **Wheeze**                                                                                                                       
  No                                             4932           76.1         4325            68.7             4554   70.3   3182   61.0
  Slight symptoms                                923            14.2         1627            25.8             1102   17.0   1383   26.5
  Severe symptoms                                49             0.8          51              0.8              134    2.1    196    3.7
  Non response                                   576            8.9          297             4.7              690    10.6   459    8.8
  **Cough**                                                                                                                        
  No                                             3418           52.8         4303            68.3             3251   50.1   2189   41.9
  Slight symptoms                                2305           35.6         1583            25.1             2234   34.5   2026   38.8
  Severe symptoms                                184            2.8          116             1.9              289    4.5    546    10.5
  Non response                                   573            8.8          298             4.7              706    10.9   459    8.8
  **Phlegm**                                                                                                                       
  No                                             1973           30.5         3291            52.2             2957   45.6   2087   40.0
  Slight symptoms                                3462           53.4         2448            38.9             2597   40.1   2137   40.9
  Severe symptoms                                485            7.5          264             4.2              206    3.2    537    10.3
  Non response                                   560            8.6          297             4.7              720    11.1   459    8.8
  **Limitation of vigorous activities**^**a**^                                                                                     
  No                                             3837           59.2         2716            43.1             3714   57.3   2663   51.0
  Did activity slowly                            1259           19.4         2661            42.2             897    13.8   988    18.9
  Avoided activity completely                    603            9.3          587             9.3              891    13.8   1113   21.3
  Non response                                   781            12.1         336             5.4              978    15.1   456    8.8
  **Limitation of moderate activities**^**a**^                                                                                     
  No                                             3775           58.3         3928            62.3             4237   65.4   3420   65.5
  Did activity slowly                            2030           31.3         1874            29.8             1266   19.5   1211   23.2
  Avoided activity completely                    88             1.4          184             2.9              135    2.1    131    2.5
  Non response                                   587            12.0         314             5.0              842    13.0   458    8.8
  **Limitation of walking**^**a**^                                                                                                 
  No                                             4867           75.1         3455            54.8             4449   68.7   3472   66.5
  Did activity slowly                            795            12.3         2438            38.7             1132   17.5   1228   23.5
  Avoided activity completely                    94             1.4          62              1.0              152    2.3    63     1.2
  Non response                                   724            11.2         345             5.5              747    11.5   457    8.8

^a^ due to breathing problems.

Air pollution concentrations
----------------------------

Helsinki had the lowest median concentrations for all PM components whilst Athens had the highest. However, maximum concentrations of PM~2.5~ were observed in Amsterdam (103.4 μg/m^3^) and of PM~10-2.5~ (152.6 μg/m^3^) in Helsinki (Table [3](#T3){ref-type="table"}).

###### 

Daily (24 hours noon-to-noon, central site) median air pollution concentration and meteorology in the four cities

                   **Helsinki**   **Athens**  **Amsterdam**    **Birmingham**                                                                          
  --------------- -------------- ------------ --------------- ---------------- ------ ------ --------------- ----- ------ -------------- ------ ------ --------------
  PNC              10^4^·cm^-3^      5.0      1.3                (0.2, 4.4)     10.5  2.0      (0.3, 6.6)     2.4  1.8      (0.8, 4.4)    21.2  1.9      (0.2, 5.1)
  PM~10~             μg·m^-3^        38.1     12.4              (0.2, 156.4)    6.3   51.7    (8.5, 158.7)    3.3  26.6    (7.4, 126.0)   14.6  16.6    (2.8, 126.2)
  PM~2.5~            μg·m^-3^        34.6     7.4               (0.3, 33.2)     6.3   22.7     (2.4, 79.1)    3.1  16.7    (4.0, 103.4)   12.8  8.4     (0.7, 71.9)
  PM~10-2.5~         μg·m^-3^        39.1     4.6               (0.0, 152.6)    6.7   28.8    (0.7, 126.4)    3.7  9.4     (0.9, 24.2)    15.6  6.9     (0.3, 118.9)
  Absorbance       10^-5^·m^-1^      38.9     1.2                (0.2, 3.8)     6.3   3.5      (0.9, 8.4)     3.1  1.9      (0.5, 7.2)    12.8  1.3      (0.2, 4.9)
  NO~2~              μg·m^-3^        1.4      22.7              (4.5, 77.9)     27.4  39.9    (11.8, 110.9)   0.4  38.4    (10.4, 97.3)   0.2   34.4    (7.3, 83.3)
  Ozone              μg·m^-3^        1.7      42.5              (4.1, 93.2)     11.8  46.9    (4.7, 108.2)    9.4  33.1    (0.9, 104.3)   0.0   37.3    (0.9, 106.6)
  Temperature           °C           0.0      2.0              (−22.8, 25.6)    0.0   15.0    (−3.1, 33.2)    0.0  9.1     (−6.1, 25.3)   0.0   9.2     (−1.4, 26.9)
  Rel. humidity         \%           0.0      80.7             (36.5, 100.0)    0.0   66.1    (21.8, 93.2)    0.0  80.8    (38.5, 98.7)   0.0   79.3    (45.8, 97.9)

Air pollution effects on symptoms-limitation in activities due to breathing problems
------------------------------------------------------------------------------------

### Prevalence analyses

We observed very small differences in fixed and random effects combined estimates. In Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"} combined odds ratios for the association of particulate matter indices, NO~2~, ozone and prevalence of symptoms and limitation in activities are presented, using random effects models adjusting for the above mentioned confounders and "as needed" medication. When all participants were included in the analysis as a total, we found that a 10 μg/m^3^ increase in PM~10~ was significantly associated at the nominal level with shortness of breath in the lag 1 whilst the association in the lags 2 and 0 to 6 was of borderline significance. However, none of the associations was significant for the asthma group. Significant association was also observed for wheezing and limitation in walking due to breathing problems (lag 1). The association was driven by the PM~10-2.5~ component of PM~10~ and much less by PM~2.5~. Coarse particles concentrations were positively associated with most symptom and restriction of activities variables in lag1. In addition, the modest correlations between PM~10-2.5~ and PM~2.5~ (0.08, 0.40, 0.35 and 0.13 for Amsterdam, Athens, Birmingham and Helsinki respectively) did allow us to apply a two-pollutant model in order to separate and further evaluate the effects of the two components of PM~10~. The magnitude of the associations for PM~10-2.5~ with prevalence of symptoms and restriction of activities remained approximately the same or increased when we applied a two-pollutant model with PM~2.5~ (Table [6](#T6){ref-type="table"}).

###### 

**Associations of particulate matter indices, NO**~**2**~**and O**~**3**~**with prevalence of symptoms in all participants and the subgroup of asthmatics (random effects pooled estimates)**

  **Symptom**                         **Pollutant**    **      Lag0**   **      Lag1**    **      Lag2**   **      Lag06**                                         
  ----------------------------------- ---------------- ---------------- ----------------- ---------------- ----------------- ----------- ----------------- ------- -------------
  **Woken with breathing problems**                                                                                                                                 
                                      PM~10~                                                                                                                        
   Total                                               1.001            0.966-1.037       1.010            0.964-1.059       0.978       0.928-1.030       1.009   0.881-1.155
   Asthmatics                                          0.977            0.937-1.019       0.982            0.923-1.044       0.953       0.881-1.031       0.947   0.855-1.049
                                      PM~2.5~                                                                                                                       
   Total                                               0.997            0.952-1.044       0.980            0.915-1.049       0.953       0.886-1.025       0.889   0.682-1.160
   Asthmatics                                          0.988            0.932-1.048       0.955            0.863-1.057       0.944       0.868-1.026       0.943   0.787-1.130
                                      PM~10\ -\ 2.5~                                                                                                                
   Total                                               1.020            0.883-1.179       1.047            0.989-1.109       0.996       0.935-1.062       1.019   0.860-1.208
   Asthmatics                                          0.959            0.797-1.154       1.009            0.952-1.070       0.915       0.731-1.147       0.689   0.381-1.247
                                      PNC                                                                                                                           
   Total                                               0.971            0.865-1.090       1.027            0.952-1.109       0.958       0.863-1.064       0.910   0.638-1.298
   Asthmatics                                          1.012            0.844-1.212       1.047            0.961-1.141       1.019       0.939-1.106       1.195   0.953-1.497
                                      Absorbance                                                                                                                    
   Total                                               1.014            0.952-1.079       1.018            0.966-1.073       0.971       0.922-1.022       0.929   0.777-1.111
   Asthmatics                                          1.051            0.874-1.264       1.026            0.940-1.120       0.978       0.916-1.044       0.967   0.805-1.162
                                      NO~2~                                                                                                                         
   Total                                               0.980            0.940-1.021       0.983            0.943-1.026       0.970       0.926-1.016       0.969   0.856-1.098
   Asthmatics                                          1.017            0.918-1.126       0.995            0.935-1.059       0.964       0.918-1.012       0.984   0.850-1.140
                                      O~3~                                                                                                                          
   Total                                               **1.063**        **1.020-1.108**   1.023            0.957-1.094       1.010       0.959-1.064       1.037   0.896-1.200
  Asthmatics                                           0.982            0.896-1.077       1.001            0.925-1.082       1.009       0.926-1.099       1.075   0.935-1.235
  **Shortness of breath**                                                                                                                                           
                                      PM~10~                                                                                                                        
   Total                                               0.998            0.970-1.026       **1.037**        **1.002-1.074**   1.014       0.986-1.042       1.050   0.998-1.106
   Asthmatics                                          0.992            0.956-1.028       1.030            0.994-1.067       0.997       0.962-1.032       1.049   0.936-1.176
                                      PM~2.5~                                                                                                                       
   Total                                               1.001            0.942-1.063       1.035            0.974-1.099       1.026       0.984-1.070       1.027   0.944-1.117
   Asthmatics                                          1.006            0.951-1.063       1.032            0.977-1.091       1.018       0.965-1.074       1.005   0.828-1.219
                                      PM~10\ -\ 2.5~                                                                                                                
   Total                                               0.995            0.949-1.042       **1.060**        **1.015-1.107**   1.002       0.949-1.057       1.044   0.947-1.151
   Asthmatics                                          0.972            0.915-1.031       1.028            0.973-1.086       0.978       0.925-1.033       1.010   0.872-1.168
                                      PNC                                                                                                                           
   Total                                               0.972            0.901-1.048       **0.910**        **0.844-0.982**   **0.919**   **0.860-0.982**   0.908   0.770-1.071
   Asthmatics                                          0.976            0.898-1.062       0.925            0.817-1.046       0.952       0.879-1.031       1.032   0.860-1.237
                                      Absorbance                                                                                                                    
   Total                                               1.019            0.936-1.109       1.042            0.954-1.138       1.026       0.978-1.077       1.064   0.929-1.218
   Asthmatics                                          1.014            0.930-1.106       1.055            0.975-1.143       1.048       0.985-1.116       1.218   0.950-1.562
                                      NO~2~                                                                                                                         
   Total                                               1.011            0.934-1.094       0.996            0.915-1.085       0.985       0.940-1.032       1.011   0.874-1.170
   Asthmatics                                          0.991            0.886-1.108       0.987            0.880-1.106       0.984       0.915-1.058       1.013   0.846-1.213
                                      O~3~                                                                                                                          
   Total                                               0.988            0.957-1.021       0.961            0.921-1.003       0.975       0.946-1.004       0.962   0.914-1.014
   Asthmatics                                          0.967            0.931-1.004       **0.932**        **0.898-0.967**   **0.932**   **0.888-0.979**   0.915   0.828-1.011
  **Wheezing**                                                                                                                                                      
                                      PM~10~                                                                                                                        
   Total                                               1.026            0.980-1.074       **1.027**        **1.000-1.055**   1.011       0.981-1.041       0.989   0.869-1.125
   Asthmatics                                          1.012            0.955-1.073       1.011            0.979-1.043       0.994       0.964-1.026       0.984   0.894-1.082
                                      PM~2.5~                                                                                                                       
   Total                                               0.998            0.925-1.077       1.004            0.931-1.082       0.982       0.882-1.094       0.873   0.629-1.213
   Asthmatics                                          0.971            0.886-1.064       0.966            0.888-1.050       0.973       0.886-1.067       0.902   0.681-1.195
                                      PM~10\ -\ 2.5~                                                                                                                
   Total                                               1.041            0.990-1.094       **1.073**        **1.028-1.120**   1.023       0.980-1.068       1.053   0.966-1.147
   Asthmatics                                          1.045            0.972-1.124       1.044            0.995-1.096       1.003       0.957-1.051       1.008   0.909-1.119
                                      PNC                                                                                                                           
   Total                                               0.934            0.791-1.104       0.947            0.816-1.099       0.985       0.841-1.154       1.092   0.639-1.865
   Asthmatics                                          0.975            0.815-1.165       0.989            0.821-1.191       1.046       0.842-1.301       1.406   0.730-2.705
                                      Absorbance                                                                                                                    
   Total                                               0.980            0.910-1.055       1.000            0.930-1.075       0.999       0.888-1.123       0.926   0.644-1.332
   Asthmatics                                          0.970            0.890-1.058       0.984            0.906-1.070       0.975       0.853-1.113       1.008   0.755-1.347
                                      NO~2~                                                                                                                         
   Total                                               0.995            0.922-1.074       0.983            0.923-1.047       1.003       0.933-1.078       1.004   0.828-1.217
   Asthmatics                                          0.995            0.934-1.060       0.980            0.916-1.048       0.986       0.895-1.086       0.999   0.838-1.191
                                      O~3~                                                                                                                          
   Total                                               1.008            0.966-1.051       1.012            0.965-1.061       1.009       0.949-1.073       1.031   0.933-1.138
   Asthmatics                                          0.985            0.948-1.025       0.998            0.959-1.038       1.046       0.947-1.156       1.060   0.916-1.228
  **Cough**                                                                                                                                                         
                                      PM~10~                                                                                                                        
   Total                                               1.001            0.975-1.027       1.014            0.985-1.045       0.999       0.957-1.043       1.007   0.913-1.110
   Asthmatics                                          0.993            0.952-1.034       0.991            0.956-1.026       0.989       0.935-1.047       0.969   0.900-1.043
                                      PM~2.5~                                                                                                                       
   Total                                               **0.960**        **0.922-0.999**   0.971            0.933-1.011       0.962       0.919-1.008       0.901   0.753-1.079
   Asthmatics                                          0.940            0.847-1.042       0.949            0.884-1.019       0.946       0.879-1.019       0.918   0.761-1.107
                                      PM~10\ -\ 2.5~                                                                                                                
   Total                                               1.099            0.943-1.282       1.089            0.956-1.240       1.043       0.958-1.137       1.210   0.772-1.896
   Asthmatics                                          1.016            0.966-1.069       1.024            0.974-1.076       1.003       0.912-1.103       1.005   0.902-1.120
                                      PNC                                                                                                                           
   Total                                               0.981            0.916-1.051       1.009            0.944-1.079       0.968       0.895-1.047       0.894   0.714-1.119
   Asthmatics                                          0.979            0.906-1.058       0.972            0.900-1.050       0.918       0.807-1.044       0.824   0.618-1.098
                                      Absorbance                                                                                                                    
   Total                                               **0.939**        **0.898-0.982**   0.976            0.932-1.022       0.959       0.917-1.003       1.083   0.797-1.472
   Asthmatics                                          0.937            0.833-1.054       0.976            0.892-1.068       **0.942**   **0.891-0.997**   1.078   0.782-1.486
                                      NO~2~                                                                                                                         
   Total                                               0.971            0.937-1.007       0.981            0.945-1.017       0.965       0.931-1.000       0.959   0.899-1.024
   Asthmaticss                                         0.980            0.935-1.026       0.986            0.941-1.033       0.972       0.925-1.020       0.981   0.903-1.066
                                      O~3~                                                                                                                          
   Total                                               **1.061**        **1.013-1.111**   **1.049**        **1.016-1.083**   **1.059**   **1.027-1.091**   1.066   0.982-1.157
   Asthmatics                                          **1.062**        **1.016-1.110**   **1.051**        **1.002-1.102**   **1.058**   **1.022-1.095**   1.106   0.939-1.302

Bold are significant pooled effects.

###### 

**Associations of particulate matter indices, NO**~**2**~**and O**~**3**~**with limitation in activities due to breathing problems in all participants and the subgroup of asthmatics (random effects pooled estimates)**

  **Symptom**               **Pollutant**    **Lag0**   **Lag1**      **Lag2**    **Lag06**                                               
  ------------------------- ---------------- ---------- ------------- ----------- ----------------- ----------- ----------------- ------- -----------------
  **Vigorous activities**                                                                                                                  
                            PM~10~                                                                                                         
   Total                                     1.018      0.950-1.092   1.028       0.957-1.103       1.026       0.956-1.102       0.989   0.854-1.146
   Asthmatics                                0.987      0.869-1.121   1.006       0.873-1.158       1.010       0.873-1.168       0.924   0.726-1.177
                            PM~2.5~                                                                                                        
   Total                                     1.016      0.910-1.135   1.016       0.892-1.158       1.039       0.922-1.169       1.005   0.831-1.216
   Asthmatics                                0.992      0.856-1.150   0.995       0.843-1.174       1.019       0.858-1.211       0.944   0.743-1.198
                            PM~10\ -\ 2.5~                                                                                                 
   Total                                     1.093      0.933-1.281   1.114       0.949-1.308       1.049       0.948-1.160       1.230   0.851-1.779
   Asthmatics                                0.980      0.817-1.175   1.005       0.816-1.238       1.019       0.919-1.130       0.956   0.612-1.494
                            PNC                                                                                                            
   Total                                     1.001      0.888-1.129   1.018       0.916-1.133       1.054       0.985-1.129       0.906   0.778-1.054
   Asthmatics                                0.979      0.895-1.070   1.014       0.924-1.112       1.065       0.976-1.163       0.927   0.748-1.149
                            Absorbance                                                                                                     
   Total                                     0.999      0.894-1.117   1.021       0.917-1.137       1.010       0.885-1.152       0.994   0.691-1.432
   Asthmatics                                1.031      0.924-1.151   1.063       0.938-1.206       1.069       0.919-1.243       0.984   0.643-1.507
                            NO~2~                                                                                                          
   Total                                     0.988      0.940-1.038   1.010       0.971-1.051       1.037       0.979-1.097       1.007   0.844-1.202
   Asthmatics                                0.995      0.916-1.081   1.028       0.960-1.100       1.046       0.945-1.158       0.942   0.713-1.245
                            O~3~                                                                                                           
   Total                                     1.033      0.935-1.141   1.031       0.946-1.124       1.024       0.932-1.125       1.107   0.879-1.394
   Asthmatics                                0.980      0.887-1.083   0.988       0.927-1.053       0.979       0.922-1.040       0.981   0.850-1.133
  **Moderate activities**                                                                                                                  
                            PM~10~                                                                                                         
   Total                                     0.973      0.888-1.067   0.973       0.923-1.026       0.973       0.907-1.044       0.904   0.729-1.122
   Asthmatics                                0.946      0.818-1.094   0.958       0.857-1.071       0.979       0.897-1.069       0.859   0.680-1.086
                            PM~2.5~                                                                                                        
   Total                                     0.922      0.749-1.136   0.950       0.848-1.065       0.963       0.862-1.077       0.953   0.808-1.124
   Asthmatics                                0.896      0.712-1.126   0.979       0.839-1.142       0.965       0.846-1.102       0.938   0.762-1.154
                            PM~10\ -\ 2.5~                                                                                                 
   Total                                     1.068      0.913-1.249   1.023       0.932-1.122       1.014       0.966-1.064       0.912   0.667-1.248
   Asthmatics                                1.000      0.943-1.062   0.987       0.932-1.045       1.007       0.955-1.062       0.727   0.411-1.289
                            PNC                                                                                                            
   Total                                     1.077      0.937-1.239   1.034       0.899-1.189       1.010       0.927-1.100       0.935   0.762-1.146
   Asthmatics                                1.075      0.977-1.183   1.025       0.922-1.139       1.016       0.873-1.184       0.835   0.680-1.025
                            Absorbance                                                                                                     
   Total                                     0.973      0.891-1.062   0.973       0.869-1.088       0.974       0.851-1.116       1.036   0.740-1.451
   Asthmatics                                0.994      0.871-1.135   0.993       0.854-1.155       0.984       0.814-1.190       0.985   0.618-1.570
                            NO~2~                                                                                                          
   Total                                     1.004      0.917-1.100   0.991       0.915-1.074       1.007       0.932-1.088       1.064   0.873-1.296
   Asthmatics                                1.004      0.897-1.123   0.988       0.886-1.100       1.000       0.889-1.125       0.999   0.718-1.390
                            O~3~                                                                                                           
   Total                                     0.970      0.899-1.046   1.000       0.916-1.091       1.002       0.939-1.070       1.022   0.879-1.189
   Asthmatics                                0.940      0.874-1.012   0.979       0.901-1.064       0.979       0.921-1.041       1.007   0.812-1.250
  **Walking**                                                                                                                              
                            PM~10~                                                                                                         
   Total                                     1.010      0.924-1.104   **1.039**   **1.007-1.073**   1.012       0.976-1.049       1.074   0.966-1.194
   Asthmatics                                1.009      0.921-1.105   **1.055**   **1.018-1.094**   1.023       0.987-1.061       1.009   0.823-1.237
                            PM~2.5~                                                                                                        
   Total                                     1.000      0.917-1.091   1.019       0.953-1.088       0.963       0.850-1.090       0.839   0.574-1.225
   Asthmatics                                1.008      0.882-1.152   **1.097**   **1.032-1.167**   **1.078**   **1.013-1.147**   0.934   0.663-1.316
                            PM~10\ -\ 2.5~                                                                                                 
   Total                                     1.072      0.904-1.273   **1.076**   **1.026-1.128**   1.044       0.997-1.092       1.079   0.819-1.420
   Asthmatics                                1.012      0.884-1.159   **1.060**   **1.005-1.119**   1.013       0.959-1.069       0.911   0.554-1.499
                            PNC                                                                                                            
   Total                                     0.978      0.797-1.199   0.986       0.915-1.063       1.007       0.937-1.083       0.975   0.670-1.418
   Asthmatics                                0.906      0.798-1.029   1.010       0.921-1.106       1.013       0.928-1.106       0.804   **0.658-0.981**
                            Absorbance                                                                                                     
   Total                                     1.014      0.915-1.124   1.038       0.956-1.128       1.013       0.942-1.089       0.852   0.544-1.333
   Asthmatics                                1.036      0.939-1.143   **1.100**   **1.031-1.174**   1.078       0.965-1.204       0.942   0.610-1.456
                            NO~2~                                                                                                          
   Total                                     0.979      0.940-1.019   1.011       0.959-1.065       1.034       0.993-1.077       1.075   0.931-1.241
   Asthmatics                                0.988      0.924-1.057   1.048       0.967-1.136       1.076       0.968-1.196       1.093   0.886-1.349
                            O~3~                                                                                                           
   Total                                     1.012      0.975-1.050   1.004       0.961-1.048       1.020       0.983-1.059       1.038   0.971-1.109
   Asthmatics                                0.999      0.948-1.053   0.982       0.933-1.033       1.003       0.939-1.071       1.048   0.913-1.203

Bold are significant pooled effects.

###### 

**Associations of PM**~**10-2.5**~**and PM**~**2.5**~**with prevalence of symptoms and limitation in activities due to breathing problems after applying two pollutant models (random effects pooled estimates)**

  **Symptom**                         **Lag0**    **Lag1**          **Lag2**    **Lag06**                                           
  ----------------------------------- ----------- ----------------- ----------- ----------------- ------- ------------- ----------- -----------------
  **Woken with breathing problems**                                                                                                  
   PM~10\ -\ 2.5~                     1.029       0.877-1.208       **1.060**   **1.006-1.117**   1.017   0.957-1.080   1.118       0.846-1.477
   PM~2.5~                            0.999       0.951-1.048       0.969       0.909-1.032       0.939   0.872-1.011   0.751       0.403-1.400
  **Shortness of breath**                                                                                                            
   PM~10\ -\ 2.5~                     0.985       0.937-1.037       1.047       0.999-1.096       0.993   0.931-1.059   1.042       0.938-1.156
   PM~2.5~                            1.006       0.945-1.070       1.025       0.977-1.076       1.024   0.980-1.070   1.042       0.960-1.131
  **Wheezing**                                                                                                                       
   PM~10\ -\ 2.5~                     **1.063**   **1.016-1.112**   **1.078**   **1.002-1.159**   1.031   0.959-1.109   **1.107**   **1.010-1.213**
   PM~2.5~                            0.982       0.895-1.078       0.958       0.854-1.075       0.962   0.850-1.089   0.921       0.721-1.177
  **Cough**                                                                                                                          
   PM~10\ -\ 2.5~                     1.140       0.950-1.367       1.127       0.955-1.329       1.060   0.977-1.150   1.293       0.885-1.890
   PM~2.5~                            **0.945**   **0.905-0.987**   **0.954**   **0.914-0.995**   0.946   0.893-1.001   0.900       0.779-1.040
  **Vigorous activities**                                                                                                            
   PM~10\ -\ 2.5~                     1.113       0.894-1.386       1.100       0.923-1.311       1.047   0.903-1.214   1.248       0.839-1.854
   PM~2.5~                            1.009       0.890-1.144       1.006       0.862-1.175       1.047   0.918-1.193   0.939       0.813-1.084
  **Moderate activities**                                                                                                            
   PM~10\ -\ 2.5~                     1.097       0.891-1.350       1.036       0.917-1.170       1.006   0.956-1.059   0.965       0.699-1.333
   PM~2.5~                            0.919       0.748-1.129       0.950       0.844-1.070       0.967   0.873-1.070   0.937       0.797-1.103
  **Walking**                                                                                                                        
   PM~10\ -\ 2.5~                     1.090       0.900-1.321       **1.073**   **1.020-1.128**   1.047   0.990-1.107   1.128       0.946-1.344
   PM~2.5~                            0.998       0.950-1.049       1.001       0.937-1.071       0.969   0.862-1.088   0.790       0.466-1.339

Bold are significant pooled effects.

The above-mentioned positive associations with PM~10-2.5~ (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}) were reduced and no longer significant after restricting the analysis to the asthmatic only participants. A significant association remained with restricting walking activities and wheeze (borderline).

Ozone was significantly associated with cough at lag 0, lag 1, lag 2 and with woken with breathing problems at lag 0. Furthermore, the associations with wheezing, limitation in vigorous activities and walking due to breathing problems remained positive across all examined lags although, non significant. Negative but non significant associations were observed with shortness of breath across all examined lags. However, a significant preventive effect of ozone for shortness of breath was revealed for lags 1 and 2, in the asthma group. Moreover, in the asthmatics, negative associations were also observed for ozone with woken with breathing problems (lag 0), wheezing (lag 0 and lag 1), and with limitation in activities due to breathing problems (most of the lags), although non significant (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}).

Neither PM~2.5~ nor NO~2~ were consistently associated with any symptom or limitation in activities variable. As for PNC a (mostly non-significant) negative association was observed with most symptoms whilst the positive associations with woken with breathing problems and cough in lag 1 as well as in limitation of activities due to breathing problems (mainly vigorous and moderate) in lags 0, 1, 2 did not reach the nominal level of significance. Moreover, for PNC a change of the negative associations with woken with breathing problems towards positive values, across all lags, was observed when the analysis was restricted to the asthmatic participants, although non significant (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}).

Centre specific and overall effect estimates with 95 percent confidence intervals (95% CI) for the association of each symptom and air pollutant in lag1 are presented in Figure [1](#F1){ref-type="fig"}. Odds ratios (OR) for the effect of PM~10-2.5~ were consistently above one in almost every city as well as in the pooled data using random effects meta-analysis.

![**Odds ratio (95% CI) for prevalence of symptoms and limitation in activities associated with an increase of 10 μg/m**^**3**^**in previous day (lag1) concentrations of each pollutant (10,000/cm**^**3**^**for PNC) in each participating city and overall estimate (random effects pooled estimates).**](1476-069X-11-75-1){#F1}

Incidence analyses
------------------

Patterns similar to those in the combined prevalence analyses were observed for the associations of incident symptoms and particles especially the coarse fraction. Shortness of breath was consistently associated with PM~10~ and PM~10-2.5~ in lag 1 with no indication of heterogeneity between the centres (OR = 1.045, 95% CI: 1.008, 1.083 and OR = 1.065, 95% CI: 1.009, 1.124 respectively). There was also a tendency towards positive associations between PM~10-2.5~ and incidence of wheezing, cough and limitation in walking but none of the associations were statistically significant. Additionally, ozone was positively associated with cough in lags 1 and 2 as well as the average lag 0--6 days but only in lag 2 the association reached the nominal level of significance (Table [7](#T7){ref-type="table"}).

###### 

**Associations of particulate matter indices, NO**~**2**~**and O**~**3**~**with incidence of symptoms in the four panels (random effects pooled estimates)**

  **Symptom**                         **Pollutant**    **Lag0**   **Lag1**      **Lag2**    **Lag06**                                                   
  ----------------------------------- ---------------- ---------- ------------- ----------- ----------------- ----------- ----------------- ----------- -----------------
  **Woken with breathing problems**   PM~10~           0.994      0.951-1.038   0.992       0.950-1.037       **0.920**   **0.877-0.966**   0.925       0.852-1.004
                                      PM~2.5~          0.995      0.931-1.064   0.965       0.903-1.033       **0.919**   **0.857-0.984**   **0.878**   **0.784-0.983**
                                      PM~10\ -\ 2.5~   0.994      0.928-1.065   1.016       0.950-1.088       **0.823**   **0.701-0.967**   0.882       0.654-1.189
                                      PNC              0.878      0.736-1.048   1.041       0.934-1.160       0.887       0.716-1.099       0.816       0.563-1.181
                                      Absorbance       1.003      0.930-1.082   0.998       0.924-1.077       0.909       0.815-1.012       0.861       0.729-1.016
                                      NO~2~            1.013      0.936-1.096   1.015       0.953-1.082       0.956       0.900-1.016       0.923       0.817-1.043
                                      O~3~             1.016      0.912-1.131   0.988       0.937-1.041       0.994       0.945-1.045       1.069       0.980-1.165
  **Shortness of breath**             PM~10~           1.008      0.958-1.060   **1.045**   **1.008-1.083**   0.992       0.954-1.031       1.048       0.974-1.127
                                      PM~2.5~          1.019      0.963-1.079   1.039       0.982-1.098       0.999       0.941-1.061       1.069       0.976-1.171
                                      PM~10\ -\ 2.5~   0.993      0.929-1.062   **1.065**   **1.009-1.124**   0.977       0.906-1.054       1.101       0.883-1.373
                                      PNC              0.963      0.871-1.066   **0.871**   **0.785-0.966**   0.968       0.861-1.088       0.992       0.767-1.283
                                      Absorbance       1.017      0.949-1.091   0.995       0.931-1.064       0.988       0.925-1.055       1.372       0.756-2.490
                                      NO~2~            1.022      0.970-1.076   0.969       0.918-1.022       0.998       0.947-1.052       1.036       0.921-1.165
                                      O~3~             0.989      0.945-1.035   0.987       0.944-1.031       1.021       0.980-1.065       1.021       0.950-1.097
  **Wheezing**                        PM~10~           1.009      0.963-1.057   0.997       0.903-1.100       1.000       0.930-1.076       1.025       0.838-1.254
                                      PM~2.5~          1.009      0.949-1.073   0.989       0.884-1.106       1.023       0.925-1.132       1.065       0.839-1.351
                                      PM~10\ -\ 2.5~   1.010      0.946-1.079   1.044       0.763-1.427       0.970       0.872-1.079       1.065       0.910-1.246
                                      PNC              0.968      0.832-1.127   1.060       0.938-1.198       1.051       0.950-1.163       1.207       0.877-1.660
                                      Absorbance       0.991      0.925-1.061   1.018       0.950-1.091       1.025       0.957-1.099       1.106       0.922-1.328
                                      NO~2~            1.009      0.951-1.071   0.986       0.932-1.043       1.028       0.974-1.086       1.089       0.988-1.199
                                      O~3~             0.968      0.921-1.017   0.978       0.899-1.064       0.975       0.931-1.022       0.940       0.861-1.026
  **Cough**                           PM~10~           1.014      0.961-1.070   1.005       0.966-1.045       0.982       0.943-1.024       1.017       0.948-1.092
                                      PM~2.5~          0.976      0.891-1.069   0.969       0.912-1.030       0.990       0.932-1.052       0.991       0.898-1.094
                                      PM~10\ -\ 2.5~   1.060      0.938-1.198   1.037       0.975-1.104       0.972       0.909-1.040       1.160       0.875-1.538
                                      PNC              0.956      0.834-1.095   1.024       0.924-1.135       0.983       0.888-1.089       1.109       0.819-1.500
                                      Absorbance       0.991      0.879-1.116   0.980       0.911-1.054       0.942       0.877-1.012       1.029       0.828-1.279
                                      NO~2~            0.994      0.942-1.049   0.968       0.884-1.061       0.975       0.923-1.030       0.999       0.844-1.182
                                      O~3~             0.984      0.939-1.032   1.027       0.950-1.109       **1.044**   **1.000-1.090**   1.030       0.938-1.132

Bold are significant pooled effects.

Discussion
==========

In this multicentre study we found consistent positive associations between coarse particles central sites concentrations and prevalence of respiratory symptoms, as recorded in a 6-month diary, in four panels of participants with predominantly mild to moderate asthma or COPD in four European cities participating in the RUPIOH study. We also found a significant association of ozone with cough and woken with breathing problems, but not with other symptoms. Neither PM~2.5~ nor NO~2~ were consistently associated with any symptom or limitation in activities variable. As for PNC a (mostly non-significant) negative association was observed with most symptoms whilst positive associations with woken with breathing problems and cough as well as with limitation of vigorous and moderate activities due to breathing problems, did not reach the nominal level of significance. Interestingly, for PNC a change of the negative associations with woken with breathing problems towards positive values, across all lags, was observed when the analysis was restricted to the asthmatic participants, although non significant at the nominal level. An analysis of the asthmatic subgroup showed generally lower odds ratios for PM~10-2.5~.

One particularity and strength of the RUPIOH study is the in depth assessment of particulate air pollution by measuring PM~10~, PM~2.5~ (then deriving coarse particles), filters absorbance as well as the number of ultrafine particles. Previous work from RUPIOH that included air pollution monitoring for one week inside and directly outside participants' homes reported no association with lung function \[[@B19]\]. As the authors stated a potential explanation could be the high prevalence of medication use, the short period of measurements (one week) that limited the ability to assess lagged effects over several days or absence of an effect. The high prevalence of medication use may also have covered some associations in the present study.

A limitation of the study is the inclusion of both COPD and asthma patients. COPD and asthma are two diseases with different underlying pathophysiological mechanisms and day to day variability in their symptoms \[[@B22],[@B23]\]. Mixing of the two diseases does not create bias in the analysis in the full population as we adjusted for differences in health status between individuals. The generalizability of the size of the effect estimates is more affected by the population. Though asthma and COPD are different diseases, we are not aware of studies that have demonstrated differences in the magnitude of response to air pollution. In our recently accepted paper in the same panel we did not find any difference in the effect of PM~10-2.5~ on total nitrate and nitrite concentrations in exhaled breath condensate (EBC NOx), a marker of oxidative stress between asthma and COPD patients \[[@B28]\]. In that study we could evaluate disease status as the outcome was a continuous variable. Unfortunately, an analysis restricted to COPD patients was not possible due to the small number of COPD patients participating in Helsinki and Birmingham. Hence, we also could not test whether the smaller PM~10-2.5~ effect in the asthmatic subgroup differed significantly from the COPD subgroup.

Our coarse particle findings are however consistent with the observation that in the RUPIOH study only the PM~10-2.5~ concentration at central sites was significantly associated with increased EBC NOx collected during the same week as the spirometry \[[@B28]\]. EBC NOx has been suggested as a reliable marker of oxidative stress \[[@B29]-[@B31]\]. The link between PM~10-2.5~ with oxidative stress and airway inflammation may explain the increase in respiratory symptoms we found.

In this study, we also report significant positive associations of ozone with cough throughout most of the examined lags both in the analysis of total participants and the subgroup of the asthmatics that are consistent with previous epidemiological and toxicological studies \[[@B32]\]. In addition, positive associations, but not significant in the nominal level, were observed with most of symptoms when total participants were included in the analysis. However, when we restricted the analysis to the subgroup of asthmatics, a significant preventive effect of ozone for shortness of breath was revealed for lags 1 and 2. Negative associations were also observed with woken with breathing problems, wheezing and with limitation in activities due to breathing problems, although non significant. Factors like high medication use, intrinsic differences in responsiveness to ozone among individuals, adaptation to ozone issues or other spurious effects may have been responsible for these findings \[[@B32]\].

In the last two decades a substantial body of literature has focused on the harmful health effects of PM~10~ and PM~2.5~\[[@B15],[@B32]\]. As a result guideline values have been recommended by the U.S. Environmental Protection Agency and World Health Organization for both indicators of PM pollution to protect public health \[[@B2],[@B3]\]. However, from recent studies there is increasing evidence that the health effects of coarse particles should not be underestimated. In a systematic review of epidemiological studies that have analyzed fine and coarse PM jointly, Brunekreef and Forsberg examined the epidemiological evidence for effects of coarse particles on health \[[@B15]\]. They concluded that the effects of PM~10-2.5~ were stronger than or as strong as PM~2.5~ on short-term respiratory morbidity. Furthermore, in a national multicity study, Zanobetti and Schwartz found a strong association of both fine and coarse particles with daily deaths in 112 U.S. cities \[[@B33]\]. A 10 μg/m^3^ increase in PM~10-2.5~ was significantly associated with total mortality, stroke, cardiovascular, and respiratory mortality, the latter of which showing the largest effect (a 1.2% increase). Mechanistically, these effects may be due either to biogenic factors or to metals carried by PM~10-2.5~ by activation of inflammatory and oxidative stress pathways \[[@B34]-[@B36]\]. The findings of our study support previous epidemiological and toxicological evidence that health effects due to the coarse fraction may be substantial \[[@B37]\].

The large number of calculations we have done could have given some statistically significant associations by chance. However, multiple testing is an unlikely explanation of the findings in the current study. In the full study population we found 14 significant associations of which 10 were positive; in the asthmatics subgroup we found 12 significant associations of which 8 were positive. The consistency of associations (e.g. for ozone and cough) further argues against chance as the main explanation for our findings. Additionally, in the full study population the significant associations for PM~10-2.5~ were supported by elevated though not nominally significant ORs for other lags and symptoms. Finally, ORs were mainly homogeneous across centers. Moreover, the modest correlations between PM~10-2.5~ and PM~2.5~ did allow us to apply a two-pollutant model in order to separate and further evaluate the effects of the two components of PM~10~. The magnitude of the associations for PM~10-2.5~ with prevalence of symptoms and restriction of activities remained approximately the same or increased when we applied a two-pollutant model with PM~2.5~.

The majority of studies that investigated health effects of particulate pollutants have expressed results on a mass basis. It has been suggested that when taking into consideration particle number or surface area, the pulmonary dose of toxic material related to PM~2.5~ may be much larger than the dose related to PM~10-2.5~ that for this reason alone, comparison on a mass basis may be less informative \[[@B15]\]. In our study we separately investigated the mass and the number effect. Neither central site PM~2.5~ nor PNC were consistently associated with symptoms. The association we observed with PM~10-2.5~, if not by chance, may also imply that a central measurement site is more appropriate for measurements of mass concentrations than for PNC. The analysis of RUPIOH data by Puustinen et al. showed generally high correlations between 24 hour average central site and residential outdoor concentrations for PM~2.5~ and soot with a lesser median correlation for PM~10~ and a lower correlation for PNC and PM~10-2.5~\[[@B17]\]. For PM~10-2.5~ correlations between central site and home outdoor measurements were 0.66, 0.74, 0.89 and 0.64 in Helsinki, Athens, Amsterdam and Birmingham respectively. A central site thus provides a reasonably good estimate of more local exposures even for coarse particles.

The relatively high divergence of PM~10-2.5~ concentrations between proximate sites in the UK has recently been confirmed by Liu and Harrison \[[@B38]\]. Consequently, for both PNC and PM~10-2.5~, there is a higher probability of exposure misclassification than for PM~2.5~ or soot. The finding of significant associations with respiratory health outcomes for PM~10-2.5~ but not for PNC is therefore quite striking but consistent with the recent findings of a time series study in London which found significant associations between PNC and cardiovascular health outcomes whilst PM mass metrics were associated with respiratory outcomes \[[@B39]\]. A plausible explanation could be the existence of different biological and pathophysiological mechanisms through which PM~10-2.5~ and PNC exert their adverse effects or different target organs. The results of recent toxicological studies support the theory that PM~10-2.5~ exert their effects at the site of deposition in the airways whereas PNC, after crossing the alveolar epithelial barrier, enter into the systemic circulation and affect cardiovascular function \[[@B40],[@B41]\]. This theory could explain the positive associations we found between PM~10-2.5~ and respiratory symptoms.

In summary, our study contributes to the literature on the health effects of PM in respiratory patients. Moreover, the results of our study are in agreement with the findings of recent epidemiological and toxicological studies and provide enough evidence to conclude that it is prudent to keep PM~10-2.5~ regulated in addition to fine particles.

Conclusions
===========

Our study adds to the limited existing evidence of recent epidemiological and toxicological studies that health effects due to the coarse fraction of ambient PM may be substantial. Further studies are needed to clarify possible different effects of PM on COPD and asthmatic patients. The observed associations suggest it is prudent to regulate also coarse particles in addition to fine particles.
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